Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Interview · July 13, 2021

Tesetaxel Plus Reduced-Dose Capecitabine Among Patients With HR+/HER2- Metastatic Breast Cancer

Interview with
Lee S. Schwartzberg MD, FACP

 

Additional Info

Disclosure statements are available on the authors' profiles:

Further Reading